Pardes Biosciences
We break viruses
What they do
Viral infections like COVID-19 need effective, easy-to-administer treatments and preventatives.
The company develops oral antiviral drugs to treat and prevent viral infections.
Patients with or at risk of viral infections and the healthcare providers who prescribe these treatments.
Founders
Co-founder and the Chief Medical Officer of Assembly Pharma (2012) and CMO/VP R&D for Assembly Biosciences (f\k\a Ventrus Bioscience), which reverse merged with Assembly Pharma in 2014. He helped ASMB raise > $300M to move 2 generations of novel HBV meds into Ph 1 and Ph 2 clinical studies. Uri has held roles at Schering Plough, Roche, and Gilead Science, and received medical training at UMDNJ, NYU and the NIH. Uri was a visiting partner at YC before he started Pardes to cure COVID-19
Company timeline
- Founded2020
- YC batchSummer 2020
- StatusPublic
- Team size2 people
- LocationSan Francisco, CA, USA; Remote
Similar startups
